Free Trial
NASDAQ:GRI

GRI Bio Q3 2023 Earnings Report

GRI Bio logo
$1.51 -0.02 (-1.31%)
As of 04/17/2025 04:00 PM Eastern

GRI Bio EPS Results

Actual EPS
-$804.44
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

GRI Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GRI Bio Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Tuesday, November 14, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

GRI Bio's next earnings date is estimated for Friday, May 9, 2025, based on past reporting schedules.

Earnings Documents

GRI Bio Earnings Headlines

FY2025 EPS Estimates for GRI Bio Boosted by HC Wainwright
Trump and Musk fight back
Is there more to the Musk–Trump relationship than meets the eye? Jeff Brown thinks so — and he believes it has to do with a top-level initiative to build the ultimate military-grade AI system. He’s calling it the “AI Superweapon,” and he says it could soon become the center of global tech dominance. At the core of this initiative? A handful of companies tied to America’s most powerful tech platforms — and investors who act before this goes mainstream may have a rare early edge.
Reviewing Medicure (OTCMKTS:MCUJF) and GRI Bio (NASDAQ:GRI)
GRI Bio's (GRI) "Buy" Rating Reaffirmed at HC Wainwright
See More GRI Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GRI Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GRI Bio and other key companies, straight to your email.

About GRI Bio

GRI Bio (NASDAQ:GRI), a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

View GRI Bio Profile

More Earnings Resources from MarketBeat